source

The Ensign Group, Inc. Declares Quarterly Dividend of $0.0625 Per Share

June 19, 2025 16:05 ET  | Source: The Ensign Group, Inc. SAN JUAN CAPISTRANO, Calif., June 19, 2025 (GLOBE NEWSWIRE)…

9 months ago

Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update

June 19, 2025 01:00 ET  | Source: Addex Therapeutics Strong cash position of CHF2.8 million at end of Q1 2025GABAB…

9 months ago

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

June 18, 2025 17:36 ET  | Source: Psyence Group Inc. TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc.…

9 months ago

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

June 18, 2025 16:30 ET  | Source: Cellectar Biosciences, Inc. FLORHAM PARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Cellectar…

9 months ago

Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025

June 18, 2025 01:00 ET  | Source: Addex Therapeutics Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a…

9 months ago

Explore Changping: Where Ming Dynasty Heritage Meets Modern Adventure

CHANGPING, China, June 17, 2025 /PRNewswire/ -- On June 14, the Ming Dynasty Culture Forum 2025 opened at the Ming…

9 months ago

Llusern Scientific Announces ISO 13485 Certification for itsPoint-of-Care Diagnostics System for Urinary Tract Infections

June 17, 2025 04:00 ET  | Source: Llusern Scientific CARDIFF, United Kingdom, June 17, 2025 (GLOBE NEWSWIRE) -- Llusern Scientific,…

9 months ago

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs

June 17, 2025 02:00 ET  | Source: Orion Oyj ORION CORPORATION PRESS RELEASE 17 JUNE 2025 at 9.00 EEST         Orion…

9 months ago

VERSES Signs Soothsayer Analytics As First Genius Reseller and Fortune 500 Integrator

Agreement to accelerate global enterprise adoption of Genius through sales, training, certification, and rapid deployments June 16, 2025 09:35 ET…

9 months ago

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedemain Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

June 14, 2025 10:48 ET  | Source: Celldex Therapeutics, Inc. 77% of patients (150 mg Q4W) treated with barzolvolimab who…

9 months ago